These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22408028)

  • 1. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.
    Facundo HT; Brainard RE; Watson LJ; Ngoh GA; Hamid T; Prabhu SD; Jones SP
    Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2122-30. PubMed ID: 22408028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac hypertrophy drives PGC-1α suppression associated with enhanced O-glycosylation.
    Brainard RE; Facundo HT
    Biochim Biophys Acta Mol Basis Dis; 2021 May; 1867(5):166080. PubMed ID: 33486096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
    Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
    Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
    Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.
    Hullmann JE; Grisanti LA; Makarewich CA; Gao E; Gold JI; Chuprun JK; Tilley DG; Houser SR; Koch WJ
    Circ Res; 2014 Dec; 115(12):976-85. PubMed ID: 25332207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
    Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
    Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
    Liu Q; Chen Y; Auger-Messier M; Molkentin JD
    Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
    Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
    J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
    Zheng J; Tian J; Wang S; Hu P; Wu Q; Shan X; Zhao P; Zhang C; Guo W; Xu M; Chen H; Lu R
    Eur J Pharmacol; 2020 Sep; 883():173386. PubMed ID: 32712088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy.
    Lunde IG; Aronsen JM; Melleby AO; Strand ME; Skogestad J; Bendiksen BA; Ahmed MS; Sjaastad I; Attramadal H; Carlson CR; Christensen G
    Mol Biol Rep; 2022 Dec; 49(12):11795-11809. PubMed ID: 36205855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
    Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
    Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
    Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSK-3β/NFAT Signaling Is Involved in Testosterone-Induced Cardiac Myocyte Hypertrophy.
    Duran J; Oyarce C; Pavez M; Valladares D; Basualto-Alarcon C; Lagos D; Barrientos G; Troncoso MF; Ibarra C; Estrada M
    PLoS One; 2016; 11(12):e0168255. PubMed ID: 27977752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy.
    Bernt A; Rangrez AY; Eden M; Jungmann A; Katz S; Rohr C; Müller OJ; Katus HA; Sossalla ST; Williams T; Ritter O; Frank D; Frey N
    Sci Rep; 2016 Oct; 6():35758. PubMed ID: 27767176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
    Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
    Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy.
    Shahid M; Spagnolli E; Ernande L; Thoonen R; Kolodziej SA; Leyton PA; Cheng J; Tainsh RE; Mayeur C; Rhee DK; Wu MX; Scherrer-Crosbie M; Buys ES; Zapol WM; Bloch KD; Bloch DB
    Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H984-94. PubMed ID: 26873969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-Induced Mitogenic Factor Promotes Cardiac Hypertrophy via Calcium-Dependent and Hypoxia-Inducible Factor-1α Mechanisms.
    Kumar S; Wang G; Liu W; Ding W; Dong M; Zheng N; Ye H; Liu J
    Hypertension; 2018 Aug; 72(2):331-342. PubMed ID: 29891648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.